Literature DB >> 17559492

Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review.

Catherine Hewitt1, Camile S Farah.   

Abstract

BACKGROUND: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) presents the clinician with significant management dilemmas. The purpose of this study was to distil information related to this disorder by comprehensively reviewing the literature.
METHODS: The structure and function of bisphosphonates, and their role in the development of BRONJ will be discussed, as will the possible mechanisms through which this pathology develops. A review of cases presented in the literature will be undertaken, and suggestions offered as to the management of this pathology in terms of surgical and conservative approaches.
RESULTS: Presentation of BRONJ is currently more common in patients taking intravenous forms of bisphosphonates, but there is a fear that the long-term cumulative effects of oral bisphosphonates may see BRONJ increasingly occurring in this patient group.
CONCLUSIONS: Prevention is superior to treatment, and the establishment of meticulous oral hygiene and pre-emptive surgical treatment prior to commencement of bisphosphonate therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559492     DOI: 10.1111/j.1600-0714.2007.00540.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  21 in total

1.  Bisphosphonate-related osteonecrosis of jaws in advanced stage breast cancer was detected from bone scan: a case report.

Authors:  Prakasit Chirappapha; Saowanee Kitudomrat; Thanaporn Thongjood; Rangsima Aroonroch
Journal:  Gland Surg       Date:  2017-02

2.  Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw.

Authors:  Dan Li; Kirill Gromov; Steven T Proulx; Chao Xie; Jie Li; Daniel P Crane; Kjeld Søballe; Regis J O'Keefe; Hani A Awad; Lianping Xing; Edward M Schwarz
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

Review 3.  Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.

Authors:  Giuseppe Ficarra; Francesco Beninati
Journal:  Head Neck Pathol       Date:  2007-12-05

4.  ONJ in two dental practice-based research network regions.

Authors:  J L Fellows; D B Rindal; A Barasch; C M Gullion; W Rush; D J Pihlstrom; J Richman
Journal:  J Dent Res       Date:  2011-02-11       Impact factor: 6.116

5.  Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Authors:  K M Kim; W Park; S Y Oh; H-J Kim; W Nam; S-K Lim; Y Rhee; I H Cha
Journal:  Osteoporos Int       Date:  2014-02-20       Impact factor: 4.507

6.  Bisphosphonate-induced osteonecrosis of the jaw: comparison of disease extent on contrast-enhanced MR imaging, [18F] fluoride PET/CT, and conebeam CT imaging.

Authors:  R Guggenberger; D R Fischer; P Metzler; G Andreisek; D Nanz; C Jacobsen; D T Schmid
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

7.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

Review 8.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  Maria-Theresa Krauth; Alexander Fügl; Reinhard Gruber
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 9.  Bisphosphonate Related Osteonecrosis of the Jaw: An Update.

Authors:  Vijay Kumar; Raman Kant Sinha
Journal:  J Maxillofac Oral Surg       Date:  2013-08-09

Review 10.  Influence of musculoskeletal conditions on oral health among older adults.

Authors:  Jennifer L Kelsey; Ira B Lamster
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.